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Abstract
Purpose Human epidermal growth factor receptor-2 (HER2)
overexpression is a predictor of response to anti-HER2 thera-
py in breast and gastric cancer. Currently, HER2 status is
assessed by tumour biopsy, but this may not be representative
of the larger tumour mass or other metastatic sites, risking
misclassification and selection of suboptimal therapy. The
designed ankyrin repeat protein (DARPin) G3 binds HER2
with high affinity at an epitope that does not overlap with
trastuzumab and is biologically inert. We hypothesized that
radiolabelled DARPin G3 would be capable of selectively
imaging HER2-positive tumours, and aimed to identify a
suitable format for clinical application.
Methods G3 DARPins tagged with hexahistidine (His6) or
with histidine glutamate (HE)3 and untagged G3 DARPins
were manufactured using a GMP-compatible Pichia pastoris
protocol and radiolabelled with 125I, or with 111In via DOTA
linked to a C-terminal cysteine. BALB/c mice were injected
with radiolabelled G3 and tissue biodistribution was evaluated
by gamma counting. The lead construct ((HE)3-G3) was
assessed in mice bearing HER2-positive human breast tumour
(BT474) xenografts.
Results For both isotopes, (HE)3-G3 had significantly
lower liver uptake than His6-G3 and untagged G3 coun-
terparts in non-tumour-bearing mice, and there was no
significantly different liver uptake between His6-G3 and
untagged G3. (HE)3-G3 was taken forward for evalua-
tion in mice bearing HER2-positive tumour xenografts.
The results demonstrated that radioactivity from
111In-(HE)3-G3 was better maintained in tumours and
cleared faster from serum than radioactivity from
125I-(HE)3-G3, achieving superior tumour-to-blood ratios
(343.7±161.3 vs. 22.0±11.3 at 24 h, respectively). On
microSPECT/CT, 111In-labelled and 125I-labelled (HE)3-
G3 could image HER2-positive tumours at 4 h after
administration, but there was less normal tissue uptake
of radioactivity with 111In-(HE)3-G3. Preadministration
of trastuzumab did not affect the uptake of (HE)3-G3
by HER2-positive tumours.
Conclusion Radiolabelled DARPin (HE)3-G3 is a versatile
radioligand with potential to allow the acquisition of whole-
body HER2 scans on the day of administration.
Keywords DARPin . HER2 .Molecular imaging . Breast
cancer . SPECT
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Introduction
Overexpression of human epidermal growth factor receptor-2
(HER2) enhances signal transduction through the PI3K/Akt
and the Ras/Raf/MEK/MAPK pathways, enabling cancer cell
proliferation and survival [1]. HER2 is overexpressed in
20 – 25% of patients with breast cancer and gastrooesophageal
cancer, and in these cancers HER2 is an established therapeutic
target [2, 3]. There are a range of HER2-targeted therapies,
including the monoclonal antibody trastuzumab, licensed for
the treatment of breast and gastric cancers, and the
trastuzumab–drug conjugate, T-DM1, licensed for the treat-
ment of breast cancer [3, 4]. Novel therapies targeting the
HER2 receptor, downstream effectors and compensatory sig-
nalling pathways are in clinical development [1].
Currently, patients are selected for anti-HER2 therapy based
on histological analysis, using immunohistochemistry or fluo-
rescence in situ hybridization (FISH) of biopsied or surgically
resected tissues [5]. These analyses are limited by the use of
single-site and single time-point sampling, and furthermore
they fail to provide information about heterogeneity of expres-
sion or changes in expression that occur over time [6]. Depen-
dence on histological analyses risks misclassifying patients’
HER2 status and selecting a suboptimal therapy. Discordance
in HER2 status between the primary breast tumour and syn-
chronous as well as metachronous metastases has consistently
been reported [7]. HER2 status has also been reported to
change, from negative to positive and vice versa, and also
between metastatic disease relapses [8, 9]. Although the impact
of HER2 misclassification on clinical outcomes is unclear,
20 – 30 % of patients with HER2-positive advanced breast
cancer do not respond to first-line treatment combinations,
despite advances in anti-HER2 therapies [10]. In the adjuvant
setting, some patients with breast cancer histologically classi-
fied as HER2-negative benefit from adjuvant anti-HER2 ther-
apy, casting doubt on their classification [11].
HER2 molecular imaging could potentially overcome the
limitations of histological analysis by providing new informa-
tion on HER2 expression at all metastatic sites. Radiolabelled
trastuzumab has been used for this purpose, but although the
pharmacokinetics of trastuzumab are well suited to therapy, its
long half-life compromises tumour-to-blood ratios needed for
imaging. Consequently, HER2 scans must be performed at
least 2 days after radiolabelled trastuzumab administration,
and even then tumours in highly vascular regions may be
difficult to visualize [12]. In clinical studies, SPECT imaging
with 111In-trastuzumab and PET imaging with both 64Cu-
trastuzumab and 89Zr-trastuzumab have shown lower rates
of tumour detection in patients with advanced HER2-
positive breast cancer than conventional imaging, including
CT [12–14]. Therefore, a novel approach is needed to over-
come these limitations, potentially utilizing low molecular
weight high-affinity proteins [15].
Designed ankyrin repeat proteins (DARPins) are recombi-
nant binding proteins composed of ankyrin repeats, which
stack together to make a contiguous binding surface [16,
17]. Each ankyrin repeat consists of 33 amino acids, which
form a β-turn followed by two anti-parallel α-helices and a
loop binding to the β-turn of the next ankyrin repeat [18, 19].
Synthetic DARPin libraries have been designed [18], from
which specific binders can be selected and further evolved by
methods such as ribosome display [20].
The DARPin G3 is a low molecular weight protein
(14 – 15 kDa) with picomolar affinity (91 pmol/L) for
HER2 [21–23]. It has a short half-life in mice (<3 min), lacks
biological activity and binds to HER2 in the presence of
trastuzumab and pertuzumab in vitro [21, 23]. The DARPin
G3 tagged with hexahistidine (His6) and labelled with
99mTc-
tricarbonyl ([99mTc(CO)3]
+) can be used to visualize HER2-
positive tumours [21]. Our goal was to use the DARPin G3 for
routine clinical HER2 SPECT and PET imaging, and we set
out to generate and evaluate different radiolabelled G3 formats
to select a lead for clinical development.
The His6 tag can be employed for purification of recombi-
nant proteins by immobilized metal affinity chromatography
(IMAC). We evaluated the effect of the His6 tag on DARPin
G3 biodistribution and compared it with the DARPin G3
tagged with histidine glutamate (HE)3, which has a negative
excess charge at physiological pH. The (HE)3 tag has been
reported to reduce background liver uptake in some cases,
while still allowing tag-mediated IMAC [24, 25]. We devel-
oped a GMP-compatible Pichia pastoris production platform
that allows cleavage of histidine-based tags after IMAC puri-
fication, enabling comparisons among variants of G3.
We hypothesized that the DARPin G3 would be capable of
selectively imaging HER2-positive tumours and aimed to
identify a suitable format for clinical application. Thus, we
systematically investigated the effect of tag and label on the
quality of imaging. First, we assessed the sensitivity and
specificity of DARPin G3 radiolabelled with [99mTc(CO)3]
+
via a His6 tag in HER2-positive and HER2-negative tumour-
bearingmice. Subsequently, we assessed the biodistribution of
His6-G3, (HE)3-G3 and untagged G3 DARPins radiolabelled
with 111In and 125I in non-tumour-bearing mice. Thus, both
residualizing and non-residualizing radioisotopes were tested,
as they have different cellular fates which can affect tumour-
to-normal tissue ratios. Finally, the construct with the lowest
normal tissue uptake was taken forward for evaluation as an
imaging agent.
Materials and methods
Details of DARPin G3 constructs (Supplementary Fig. 1),
production, purification, conjugation with 1,4,7,10-
tet raazacyclododecane-1,4,7-Tris-acetic acid-10-
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maleimidoethylacetamide (mal-DOTA) and radiolabelling are
provided in the Supplementary Materials and methods.
DARPin G3 radiolabelling
DOTA-conjugated DARPins (5 – 60 μg) in 0.2 M ammonium
acetate, pH 6.5, were mixed with a solution of 111InCl3
(Covidien, The Netherlands; 10 – 30 MBq) and incubated
for 2 h at 37 °C (reaction volumes 40 – 60 μl). The reactions
were stopped by adding 0.1 M disodium edetate (EDTA) and
the radiolabelled DARPins were purified by elution into PBS
using a NAP-5 column (GE Healthcare, Little Chalfont, UK)
pre-equilibrated with PBS. Radiochemical purity was deter-
mined using instant thin-layer chromatography (iTLC), using
iTLC silica gel (SG) strips (Varian, Palo Alto, CA). To test for
111In-EDTA, iTLC strips were eluted with 0.1 M ammonium
acetate containing 25 mM EDTA (final pH 5.5) in which
system 111In-EDTA eluted to the solvent front, while 111In-
G3 DARPin and insoluble material remained at the origin.
Formation of radioactive insoluble material was evaluated
using iTLC-SG eluted with 35 % ammonia (v/v)/ethanol/
water (1:2:5), in which system 111In-DOTA-G3 DARPin and
111In-EDTA both had Rf values >0.5, while any insoluble
material present in the reaction mixture remained at the origin.
If insoluble material was detected, reaction mixtures were
filtered through a 0.2-μm sterile syringe filter with a Supor
membrane (Pall Life Science, Portsmouth, UK). The radio-
chemical purity of 111In-G3 DARPins was 70 – 80 % before
purification and >95 % after purification (see below for spe-
cific activities, SA).
Iodine radiolabelling was performed in precoated Pierce
iodination tubes (Thermo Scientific, Runcorn, UK) with un-
conjugated G3 DARPins (5 – 60 μg) in PBS for 10 min at
room temperature, using either 10 MBq 125I (PerkinElmer,
Llantrisant, UK) or 15 – 20 MBq 123I (GE Healthcare). The
iodination reactions were stopped by adding sodium
metabisulphite to a final concentration of 1 μM.
Radioiodinated DARPins were purified by buffer exchange
into PBS with a NAP-5 column. Radiochemical purity was
assessed with iTLC-SG strips (Varian) using 0.1 M ammoni-
um acetate containing 25 mM disodium EDTA (final pH 5.5)
as 123/125I-G3 DARPin remained at the origin and free 123/125I
eluted at the solvent front. Radiochemical purity increased
from 60 – 70 % before purification to >95 % after purification
(see below for SA). An equivalent molar amount of ‘cold’
potassium iodide (3.4×10−10 mol) was coadministered with
123I-G3 DARPin to minimize normal tissue uptake of ‘free’
123I (formed by deiodination in vivo).
iTLC analysis was supplemented with size-exclusion high-
performance liquid chromatography (HPLC). A Beckman
System Gold 128 solvent module and a 168 UV detector
module (monitoring at 280 and 220 nm; Beckman Coulter,
High Wycombe, UK), combined with a Raytest GABi
radiochemical detector (Raytest, Straubenhardt, Germany)
were used. The radiolabelled DARPin G3 was eluted from a
YMC-Pack Diol-60 (YMC Europe, Dinslaken, Germany)
column, dimensions 300 mm length × 8.0 mm inner diameter,
spherical shape, 5 μm particle size and 6 nm pore size, using a
mobile phase of 0.2M phosphate buffer (pH 6.8) at a flow rate
of 0.5 ml/min.
In vitro assessment
The unconjugated and DOTA-conjugated G3 counterparts
had comparable subnanomolar binding affinities for the
HER2 extracellular domain (ECD) assessed by surface plas-
mon resonance, indicating that DOTA conjugation to the C-
terminus does not compromise binding to HER2 (data not
shown). Saturation binding assays of radiolabelled DARPin
G3 were performed with BT474 HER2-expressing human
breast cancer cells (ATCC, Manassas, VA) as previously
described [26]. On BT474 cell-binding assays, 111In-(HE)3-
G3 and 125I-(HE)3-G3 had saturable binding and similar bind-
ing affinities to each other.
To assess stability of the label, aliquots of radiolabelled
DARPin G3 were incubated in PBS or in human serum/PBS
(1:1). Serum stability was assessed at 37 °C for 24 h, while
PBS stability was assessed at 4, 20 and 37 °C for 24 h after
radiolabelling by iTLC, as previously outlined. After incuba-
tion, the stability of radiolabelled G3 was assessed by SDS-
PAGE using non-reducing conditions, followed by autoradi-
ography using a Cyclone storage phosphor system
(PerkinElmer).
Biodistribution studies
All animal studies were ethically reviewed and performed in
accordance with the UK Animals (Scientific Procedures) Act
1986, UK Home Office regulations and local regulations.
For non-tumour studies, female BALB/c mice (Charles
River, Erkrath, Germany) aged 6 – 11 weeks (mean weight
19 g) received an intravenous dose of 0.3 MBq of 111In-G3
DARPin (2.2 μg, SA 2.0 MBq/nmol, to 4.3 μg, SA 1 MBq/
nmol) or 125I-G3 DARPin (2.8 μg, SA 1.6 MBq/nmol, to
4.3 μg, SA 1 MBq/nmol) in 200 μl of PBS/0.1 % BSA. Mice
were killed at 4 h (four mice) or 24 h (four mice) after
administration. Tissues were removed and radioactivity mea-
sured in a gamma counter (1282 CompuGamma CS, LKB
Wallac). Uptakes are expressed as means±SD of the percent-
age of injected radioactive dose per gram of tissue (% ID/g).
For tumour studies, a single 60-day release 0.72-mg 17β-
oestradiol pellet (Innovative Research of America, Sarasota,
FL) was inserted into the scruff of female SCID-beige mice
(Charles River) aged 6 – 8 weeks (mean weight 17 g). The
following day, the mice were inoculated with BT474 cells by
subcutaneous injection (7.5×106 cells; ATCC) in PBS mixed
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with equal volumes of Matrigel (BD Biosciences, Oxford,
UK). When tumours reached 25 – 100 mm2 (5 – 7 weeks after
inoculation) the mice received 0.3 MBq of 111In-G3 DARPin
(2 μg, SA 2.2 MBq/nmol) or 0.3 MBq of 125I-G3 DARPin
(3 μg, SA 1.5 MBq/nmol) and biodistribution was calculated
as outlined. Excised BT474 tumours from untreated SCID-
beige mice were HER2-positive (immunohistochemistry 3+,
defined as consistent with circumferential membrane staining
that is complete, intense and within >10 % of tumour cells) as
assessed using the HercepTest (Dako, Ely, UK) according to
the manufacturer’s instructions [5].
In the trastuzumab blocking study, three female SCID-
beige mice with BT474 tumours received intravenous
trastuzumab (14.2 mg/kg) 24 h prior to intravenous injection
of 111In-G3 DARPin. Three control mice received 111In-G3
DARPin alone. The mice were killed at 4 h after administra-
tion of 0.3 MBq 111In-G3 DARPin (1.9 μg per mouse, SA
2.3 MBq/nmol).
MicroSPECT/CT imaging
Female SCID-beige mice bearing BT474 tumours were
injected intravenously with either 10.5 MBq of 123I-G3
(2.1 MBq/μg, SA 30.1 MBq/nmol) or 8.4 MBq of 111In-G3
(4 MBq/μg, SA 58 MBq/nmol). Preliminary work had dem-
onstrated that HER2-positive tumour signals on SPECT scans
were compromised at lower SAs of radiolabelled G3 DARPin
(data not shown). Thus, the SA for imaging was increased
compared to the biodistribution studies to enhance the quality
of images, but mice assessed for biodistribution and imaging
studies received a similar molar dose of G3 DARPin. The
radiolabelling reactions for imaging studies were performed
with both a lower amount of G3 DARPin and higher
radiation activity within the parameters outlined in the
radiolabelling section.
Imaging was performed under 2 % isoflurane anaesthesia
4 h after administration using a microSPECT/CTanimal scan-
ner (Bioscan, Poway, CA). Helical SPECT images were ac-
quired in 20 projections over 30 – 40 min using a four-headed
camera with 4×9 (1.4 mm) pinhole collimators. The CT
images were acquired in 180 projections with an exposure
time of 1,000 ms using a peak kilovoltage of 45 kVp over
6 min. Radionuclide images were reconstructed using
HiSPECT (Scivis, Göttingen, Germany) iterative reconstruc-
tion software and fused with CT images using proprietary
InVivoScope (Bioscan) software.
DARPin G3 specificity for HER2 in vivo
Mice were inoculated with tumours as previously described.
G3 DARPins were radiolabelled with [99mTc(CO)3]
+ via a C-
terminal His6 tag ([
99mTc(CO)3]
+-G3 DARPin-His6) accord-
ing to the published protocol [27]. Briefly, [99mTc(CO)3]
+ was
prepared using an IsoLink kit (Mallinckrodt, Petten, The
Netherlands) according to the manufacturer’s instructions.
Following neutralization and the addition of 150 μg of G3
DARPin, the mixture was reacted at room temperature for
30 min. Radiolabelling efficiency was determined by size
exclusion HPLC using the same methods as previously
outlined. The product was purified from 50 % to 100 %
radiochemical purity using a NAP-10 column (GE
Healthcare). MicroSPECT/CT imaging was performed 1 h
after administration of about 30 MBq [99mTc(CO)3]
+-G3
DARPin-His6 (10 μg, SA 44 MBq/nmol) to three mice with
HER2-positive (BT474) tumours and three mice with HER2-
negative (MDA-MB-468) tumours, as previously described.
Mice were killed at 24 h.
DARPin G3 specificity for HER2 in vitro
The DOTA-conjugated G3 DARPins were labelled using
naturally abundant indium chloride (natInCl3; Sigma-Aldrich,
St. Louis, MO) in 0.05 M HCl solution, and unconjugated G3
DARPins were labelled using NanatI (Sigma-Aldrich) in 0.1M
sodium hydroxide, using the same conditions required for
111In and 125I radiolabelling reactions, respectively.
Competition assay
BT474 cells (ATCC) were seeded at a density of 1×106 per
well into Cellstar six-well plates (Greiner bio-one,
Frickenhausen, Germany) and grown to confluence over
24 h. The confluent cells were incubated in triplicate with
0.1 nM [99mTc(CO)3]
+-G3 DARPin-His6 with or without
1,000 nM natIn-DARPin or natI-DARPin in Dulbecco’s mod-
ified Eagle’s medium (DMEM) with high glucose concentra-
tion (4.5 g/L) containing 1 % fetal calf serum (Biosera,
Boussens, France ) and 0.1 % sodium azide (Sigma-Aldrich)
for 1 h 30 min at 20 °C. An unlabelled epidermal growth
factor receptor (EGFR) binding DARPin (K. Chester, unpub-
lished) was used as a control.
The assays were stopped by removing the medium and
washing the cells with 2 ml ice-cold PBS. The cells were lysed
with 1 ml of 1 M sodium hydroxide and the lysate was
collected. The wells were washed twice with 1 ml of PBS.
The washes were pooled with the cell lysate for analysis. The
radioactivity was measured in a gamma counter. The mean
percentage of radioactivity was calculated for each condition
in relation to the controls treated with [99mTc(CO)3]
+-G3
DARPin-His6 alone.
Flow cytometry analysis
BT474 (ATCC), MDA-MB-468 (ATCC) and OE-19 (Sigma-
Aldrich) cells were individually prepared for flow cytometry
by removal of medium and incubation with 5 ml of 0.2 %
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EDTA for 10 min. The cells were then transferred to tubes and
centrifuged (4 °C, 4 min, 1,000 rpm). The EDTA solution was
removed and 5 ml of fresh medium was added. Cells were
counted and diluted to 1 million/ml, and 1 ml was used for
each test condition. After washing with cold PBS, 200 μl of
DARPin at 10 μg/ml was added followed by incubation for
1 h at 4 °C. Cells were washed with cold PBS and incubated
with 200 μl of mouse anti-DARPin (K. Chester, unpublished)
for 1 h at 4 °C. Subsequently the cells were washed with cold
PBS and incubated with 200 μl of Alexa Fluor® 488 goat anti-
mouse IgG (Life Technologies, Paisley, UK) for 30 min at
4 °C. After further washing with cold PBS, the cells were
suspended in 500 μl of cold PBS. Samples were analysed on a
CyAn ADP high-performance flow cytometer (Becton Dick-
inson, Oxford, UK); cells were gated according to size scat-
tering, forward scattering and pulse width so only single cells
were analysed. A total of 10,000 cell events were recorded per
sample and data were analysed using FlowJo software (Tree
Star, Ashland, OR).
Statistical analysis
An independent samples t test was performed with SPSS
Statistics 21 software (IBM, Armonk, NY) to compare normal
liver uptake between the different radiolabelled G3 DARPins
(p values <0.05 were considered statistically significant).
Results
In vitro stability of label
Over 24 h, 111In-(HE)3-G3 DARPin was stable in PBS at 4, 20
and 37 °C and in serum at 37 °C, as >95 % of radiation activity
remained bound to (HE)3-G3 and each sample contained a
single-sized radiolabelled protein that had the appropriate molec-
ular weight (Supplementary Table 1 and Supplementary Fig. 2).
Specificity for HER2
HER2 tumour specificity was first established with
[99mTc(CO)3]
+-G3 DARPin-His6, which had 3.5-fold higher
uptake in HER2-positive (BT474) tumours than in HER2-
negative (MDA-MB-468) tumours (3.5±1.1 vs. 1.0±0.2 %
ID/g at 24 h after administration). Uptake in normal tissues
was similar in the HER2-positive and HER2-negative tumour-
bearing mice (Table 1). The differences in tumour uptake were
also apparent on microSPECT/CT scanning (Fig. 1). Howev-
er, [99mTc(CO)3]
+-G3 DARPin-His6 did not appear optimal
for imaging, since the tumour-to-liver ratios were low (1.2:1 at
24 h) and the tumour-to-blood ratios were not optimal (26:1 at
24 h). Thus, there was a need to optimize G3 by assessing the
effects of histidine-based tags on the biodistribution of G3 in
normal tissue.
A competition assay showed that the His6-G3 labelled with
cold indium and cold iodine, (HE)3-G3 and untagged G3 all
competed with [99mTc(CO)3]
+-G3 DARPin-His6 for binding
to HER2-positive human breast cancer cells (BT474). By
contrast, non-labelled EGFR-targeting DARPin did not com-
pete with [99mTc(CO)3]
+-G3 DARPin-His6 for binding to
BT474 cells (Fig. 2).
Flow cytometry demonstrated that G3 DARPins labelled
with cold indium and cold iodine bound to HER2-positive
human breast cancer cells (BT474) and HER2-positive human
gastrooesophageal junction (OE-19) adenocarcinoma cells,
but did not bind to HER2-negative human breast adenocarci-
noma cells (MDA-MB-468). The non-labelled G3 DARPin-
His6 and the assessed cold-labelled DARPins demonstrated
HER2 specificity in vitro (Fig. 3). Thus, HER2 specificity of
His6-G3, (HE)3-G3 and untagged G3 DARPins in vitro was
confirmed.
Table 1 Biodistribution of [99mTc(CO)3]
+-G3 DARPin-His6 in HER2-
positive and HER2-negative tumour-bearing SCID-beige mice
Organ HER2-positive (BT474)
tumours at 24 h, mean %
ID/g±SD (n=3)
HER2-negative (MDA-MB-468)
tumours at 24 h, mean % ID/g±
SD (n=3)
Tumour 3.5±1.1 1.0±0.2
Spleen 0.9±0.2 1.0±0.3
Kidney 108.0±7.7 108.6±10.6
Liver 3.0±0.2 2.7±0.7
Lung 0.5±0.1 0.5±0.2
Blood 0.1±0.0 0.1±0.00
Muscle 0.3±0.1 0.2±0.1
A B  
Fig. 1 microSPECT/CT scan of [99mTc(CO)3]
+-G3 DARPin-His6 at 1 h
in SCID-beige mice bearing: a HER2-positive human breast tumour
(BT474), and b HER2-negative human breast tumour (MDA-MB-468).
Tumours (arrows) assessed at same sensitivity level
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Biodistribution in non-tumour-bearing mice
Normal tissue uptake of His6-G3, (HE)3-G3 and untagged G3
DARPins radiolabelled with 111In and 125I was first assessed
in non-tumour-bearing mice. 111In-(HE)3-G3 DARPin had
lower uptake in the spleen, stomach, liver and bone marrow
at 4 h and 24 h than 111In-His6-G3 and
111In-untagged-G3. In
other normal tissues, 111In-(HE)3-G3 had either similar or
lower uptake at 4 h and 24 h than its 111In radiolabelled
counterparts (Fig. 4 and Supplementary Table 2).
At 4 h, 111In-(HE)3-G3 had significantly lower liver
uptake than 111In-His6-G3 (p=0.001) and
111In-un-
tagged-G3 (p=0.001). Also at 24 h after administration,
111In-(HE)3-G3 liver uptake was significantly lower than
that of 111In-untagged-G3 (p=0.002) and 111In-His6-G3
(p=0.001). Interestingly, there was no significant differ-
ence in liver uptake between the 111In-untagged-G3 and
111In-His6-G3 at 4 and 24 h after administration
(Fig. 4). This suggests a specific favourable influence
of the (HE)3-tag, rather than some level of liver
targeting of the His6 tag. Bone uptake was largely
attributed to the marrow, as marrow uptake was similar
to intact bone uptake. Kidney uptake was greater than
200 % ID/g for all 111In-G3 DARPins at 4 h (Fig. 4
and Supplementary Table 2).
In the study of the radioiodinated DARPins (Fig. 5), where
we also have to take enzymatic dehalogenation into account,
125I-(HE)3-G3 and
125I-untagged-G3 showed the lowest up-
take in all normal tissues at 4 h. At 24 h, liver uptake of
125I-(HE)3-G3 was significantly lower than those of
125I-un-
tagged-G3 (p=0.004) and His6-G3 (p=0.003). There was no
significant difference in normal liver uptake between 125I-
His6-G3 and
125I-untagged-G3 at 4 h and 24 h (Fig. 5 and
Supplementary Table 3).
Normal tissue uptake of 125I was <1.3 % ID/g for the 125I-
labelled G3 DARPins at 24 h, while for 111In-G3 DARPins
normal tissue uptake was better maintained between 4 and
24 h (Figs. 4 and 5).
Biodistribution in mice bearing HER2-positive tumours
The biodistribution of (HE)3-G3 was assessed in HER2
tumour-bearing mice, and this construct was chosen on the
basis of its lower normal tissue uptake (Figs. 4 and 5), which
could facilitate imaging of HER2-positive tumours by achiev-
ing greater contrast between tumours and normal tissues. The
normal tissue uptake of both 111In-(HE)3-G3 and
125I-(HE)3-
G3 in tumour-bearing mice was similar to that in non-tumour-
bearingmice (Supplementary Figs. 3 and 4). Similarly, normal
tissue uptake of 111In-(HE)3-G3 in tumour-bearing mice was
lower than that of 125I-(HE)3-G3 at 4 h, except in the kidneys.
At 24 h, the differences in normal tissue uptake between
111In-(HE)3-G3 and
125I-(HE)3-G3 were smaller
(Supplementary Table 4). Kidney uptake of 111In-(HE)3-G3
was higher than that in other tissues tested; it peaked at 4 h
after administration at 232.0±24.1 % ID/g and decreased to
196.5±31.0 % ID/g at 24 h after administration (Fig. 6a, b and
Supplementary Table 4).
The measured tumour uptake of 125I-(HE)3-G3 and
111In-(HE)3-G3 was similar at 4 h (11.3±3.2 and 8.8±1.3 %
ID/g, respectively). However, the radioactivity from
111In-(HE)3-G3 in the tumour was better maintained, so that
by 24 h 111In-(HE)3-G3 tumour radioactivity was over
Fig. 2 Competition assay using BT474 cells, treated with 0.1 nM
[99mTc(CO)3]
+-G3 DARPin-His6 with or without 1,000 nM cold
DARPins. Each condition was assessed in triplicate and expressed as
percentage of radioactivity in relation to the control treated with 0.1 nM
[99mTc(CO)3]
+-G3 DARPin-His6 alone (means±SD)
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threefold higher than that of 125I-(HE)3-G3 (8.1±0.9 vs. 2.5±
0.6 % ID/g; Fig. 6a, b and Supplementary Table 4).
In comparison with 125I-(HE)3-G3,
111In-(HE)3-G3 had
higher tumour-to-normal ratios for all tissues except the
Fig. 3 Flow cytometry of G3 DARPins labelled with cold indium and
cold iodine assessed in humanHER2-positive breast cancer cells (BT474)
and gastrooesophageal junction (OE-19) adenocarcinoma cells, as well as
in human HER2-negative breast adenocarcinoma cells (MDA-MB-468).
G3-His6 was unlabelled and omission controls were treated with cells and
antibodies in the absence of G3 DARPin. Percentages are percentage of
cells with G3 DARPin binding (fcs flow cytometry study)
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kidneys at 4 h (Table 2). Tumour-to-blood ratios for
111In-(HE)3-G3 were 174.7±26.1 at 4 h and 343.7±161.3 at
24 h, compared with 4.4±3.4 at 4 h and 22.0±9.6 at 24 h for
125I-(HE)3-G3 (Table 2).
DARPin G3 tumour uptake in the presence of trastuzumab
Intravenous administration of an 18-fold molar excess of non-
radiolabelled trastuzumab 24 h prior to administration of
111In-(HE)3-G3 did not alter HER2-positive tumour uptake
at 4 h compared with that in control mice receiving only
111In-(HE)3-G3 (7.2±1.3 vs. 7.1±1.9 % ID/g, respectively;
Fig. 6c). Although trastuzumab and G3 bind to domain
IV of the HER2 ECD, G3 can bind in the presence of
trastuzumab [23].
MicroSPECT/CT imaging
HER2 tumour uptake could be detected on the 4-h 123I-(HE)3-
G3microSPECT/CTscan but there was non-specific uptake in
the stomach, kidneys, bladder and thyroid. In contrast, on the
4-h 111In-(HE)3-G3 microSPECT/CT scan, HER2 tumour up-
take was detected and there was minimal non-specific uptake
in non-renal organs (Fig. 7).
Discussion
111In-(HE)3-G3 DARPin was found to be better for HER2
imaging than all other formats tested in this study. There are
limitations in comparing HER2 radioligands assessed in
Fig. 4 Biodistribution of 111In-G3 DARPins a 4 h and b 24 h after administration in female BALB/c mice (mean % ID/g±SD). *p<0.05, DARPins
(HE)3-G3 vs. His6-G3 and untagged G3 (liver uptake)
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different HER2-positive human tumour xenografts, including
different levels of HER2 expression. However, within 24 h of
administration to mice bearing HER2-positive tumours,
111In-(HE)3-G3 DARPin achieved higher tumour-to-blood
ratios than other reported HER2 radioligands, including whole
antibodies, Fab fragments of antibodies and small high-
affinity proteins [28–31]. 111In-(HE)3-G3 also had greater
potential for HER2 imaging than 125I-(HE)3-G3, reflected by
superior microSPECT/CT scans.
The BT474 tumour-bearing mice were confirmed to have
immunohistochemistry scores of 3+ with the HercepTest. The
HER2-positive tumour uptake of 111In-(HE)3-G3 and
125I-(HE)3-G3 achieved at 4 h was 8.82±1.25 % ID/g and
11.29±3.24 % ID/g, respectively. By contrast, 111In-DOTA-
ZHER2:342-pep2 achieved 39.9 percentage of injected activity
per gram tissue (% IA/g) [32]. Although higher HER2-
positive tumour uptake could have been anticipated, the tu-
mour uptake was sufficient for microSPECT/CT imaging and
impressive tumour-to-blood ratios were achieved.
The G3 DARPins were radioiodinated directly at their
tyrosine residues. It is likely that only one of the two tyrosine
residues within each G3 DARPin was radioiodinated, owing
to the molar ratios of radioiodide and G3 DARPin used for
radiolabelling. Although direct radioiodination is convenient
and the most widely used methodology, it is recognized that
the radioligand is likely to undergo in vivo dehalogenation. In
future studies, we plan to compare methods using bifunctional
coupling agents, to determine whether this approach can im-
prove in vivo stability of radioiodinated G3 DARPins [33].
Nanobodies (12 – 15 kDa) are isolated from the heavy chain
of Camelidae antibodies. The anti-HER2 5F7GGCNanobody
radioiodinated via the residualizing agent N-succinimidyl 4-
guanidinomethyl 3-125/131I-iodobenzoate (*I-SGMIB-
Nanobody) has superior targeting of HER2-positive human
breast carcinoma in vitro and in vivo than its directly
radioiodinated counterpart, as *I-SGMIB-Nanobody has en-
hanced tumour retention of radioactivity [34].
Importantly, we observed that 111In-(HE)3-G3 was able to
bind to HER2 in the presence of trastuzumab. This confirms
the results of structural modelling which demonstrate that
DARPin G3 and trastuzumab bind to non-overlapping epi-
topes of HER2 domain IV [35]. Thus, 111In-(HE)3-G3
Fig. 5 Biodistribution of 125I-G3 DARPins a 4 h and b 24 h after administration in female BALB/c mice (mean % ID/g±SD). *p<0.05, DARPins
(HE)3-G3 vs. His6-G3 and untagged G3 (liver uptake)
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DARPin has the potential to image both treatment-naive pa-
tients and patients receiving concomitant trastuzumab without
requiring a delay to treatment.
111In-(HE)3-G3 imaging would provide completely new
information with the potential to improve understanding of
HER2 breast cancer evolution and heterogeneity. Current
literature based on biopsy sampling is inconsistent with a
wide-range of reported rates of HER2 expression discordance
between primary and metastatic sites, from 0 to 34 % [7].
Whole-body assessment of HER2 expression at tumour sites
over time and during therapy with HER2 imaging is both
more feasible and acceptable to patients than serial and mul-
tiple biopsies. Furthermore, considerably less is known about
gastric cancer HER2 biology, and 111In-(HE)3-G3 imaging
could help address this knowledge gap [36].
HER2 is an important therapeutic target in cancer. DARPin
HER2 imaging could be used to improve the selection of
patients for anti-HER2 therapy, by identifying increased
HER2 expression and the need to introduce anti-HER2 ther-
apy, as well as HER2 loss, necessitating discontinuation of
anti-HER2 therapy [1]. This could not only save patients from
unnecessary treatments, but also improve healthcare econom-
ics by ensuring appropriate use of expensive anti-HER2
therapies.
The pharmacokinetics of 111In-(HE)3-G3, including short
half-life in serum, high tumour-to-blood ratios and low non-
renal tissue uptake, are well suited to HER2 imaging. The
kidneys received the highest radiation dose. However, based on
medical internal radiation dose (MIRD) estimates, the maximum
absorbed kidney dose in patients with the proposed clinical dose
of 111In-(HE)3-G3 (300 MBq) is 1,000-fold lower than the dose
associated with a 5 % rate of radiation nephritis within 5 years of
administration (TD5/5; 9.75 mGy vs. 10 Gy) [37].
Imaging trials of most HER2 radioligands have had disap-
pointing results due to limitations related to their pharmaco-
kinetics for imaging which were already apparent in preclin-
ical assessment [28–31]. It should be noted that the majority of
clinical HER2 imaging studies have not assessed HER2 tu-
mour status histologically for correlation with HER2 scans,
thus limiting the evaluation of these imaging agents.
Trastuzumab radiolabelled with 64Cu, 89Zr or 111In has dem-
onstrated the potential for HER2 imaging by identifying
known and/or previously unknown tumour lesions in patients,
but lacks sensitivity compared with conventional imaging
owing to a long half-life and high blood pool activity
[12–14]. Fab fragments of trastuzumab were developed for
HER2 imaging because their lower molecular weight is asso-
ciated with a shorter half-life in serum and faster clearance of
background radiation from the blood compared with
trastuzumab. However, 68Ga-F(ab’)2-trastuzumab PET imag-
ing failed to identify any tumours among four of the eight
patients with metastatic HER2-positive breast cancer
assessed, due to relatively high liver uptake and blood pool
activity as well as potential competition with therapeutically
administered trastuzumab [38].
A radiolabelled HER2 binding Affibody molecule, ZHER2:342
(about 7 kDa), was used to assess three patients with HER2-
positive metastatic breast cancer by PETand/or SPECT imaging.
Although not all known tumour lesions were identified in two
patients, there was limited tumour biopsy sampling to systemat-
ically evaluate the accuracy of HER2 Affibody molecule imag-
ing. Unfortunately, there was high background liver uptake in
this initial study [39]. Recently, a phase I trial demonstrated that
the second generation Affibody 111In-ABY-025 has improved
distribution, dosimetry and accuracy in assessing patients with
HER2-positive and HER2-negative metastatic breast cancer.
There was a good correlation between HER2 status assessed
by SPECT/CT 111In-ABY-025 imaging and immunohistochem-
istry with the HercepTest, including confirmation that a
patient who had had HER2-positive primary disease
developed HER2-negative metastases [15].
In our evaluation of the DARPin G3, the (HE)3 tag is a
beneficial component as it appeared to lower normal liver
uptake of the DARPin G3 without compromising uptake in
other assessed normal tissues. This is advantageous for clini-
cal application as HER2 molecular imaging requires high
tumour-to-liver tissue ratios and the liver is a common site
for breast cancer metastases, yet is also involved in drug
metabolism and excretion. Histidine-based tags enable IMAC
purification and can also be used for chelation of
[99mTc(CO)3]
+ [21, 27]. The His6 tag is well established and
has been used safely in patients [40], but (HE)3-G3 DARPin
was superior to His6-G3. Affibody molecules with an (HE)3
tag also have lower normal liver uptake than counterparts with
alternative histidine-based tags [24, 25]. The G3 DARPins
assessed in this study only differed by the presence or com-
position of their tags and thus the study was able to confirm
that (HE)3-G3 DARPin had the lowest normal liver uptake.
The mechanism of (HE)3 tag-mediated reduction in liver
uptake of DARPin G3 has not been established. For Affibody
molecules it has been proposed that positive charge and hy-
drophobicity in the tag play a crucial role in liver uptake [25].
However, the untagged and His6-tagged Affibody molecules
have basic isoelectric points (pI), which are brought to a more
acidic region by switching to an (HE)3 tag, such that the
overall pI of the different Affibody constructs tested differed
greatly. By contrast the (HE)3-tagged, His6-tagged and un-
tagged G3 DARPins have similar pI values of 4.79, 5.41 and
4.71, respectively [25]. Furthermore, the (HE)3-tagged, His6-
tagged and untagged G3 DARPins have similar grand average
Fig. 6 Biodistribution of (HE)3-G3 in female SCID-beige mice bearing
HER2-positive human breast tumours (BT474) (mean % ID/g±SD)
pretreated with trastuzumab 24 h prior to DARPin administration (a
111In-(HE)3-G3 DARPin, b
125I-(HE)3-G3 DARPin. c
111In-(HE)3-G3
DARPin). Controls received only 111In-(HE)3-G3
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of hydropathy (GRAVY) scores of −0.12, −0.12 and +0.02,
respectively, indicating that other factors are involved, while
the corresponding Affibody molecules have slightly more
divergent scores of −1.03, −0.97 and −0.85.
Although in preclinical studies histidine-tagged proteins
have been shown to exert greater immunogenicity than their
untagged counterparts, several histidine-tagged proteins have
been well tolerated in human trials [40]. For example,
Endostar a novel recombinant human endostatin which in-
hibits angiogenesis has a histidine tag, and was safe and well
tolerated in large clinical trials [41]. Interestingly, a Blast
search (NCBI) for a short input sequence with HEHEHE as
the query, yielded a variety of hits in the database of almost
identical sequences, e.g. HEHEH in the human zinc transport-
er (gene ID SLC39A9) and HEHEQE in kinase 3 (gene ID
TAOK3). The HHHHHH sequence cannot be found using a
Blast search in the Homo sapiens database. Instead clusters of
histidine are found that are coordinated with metal ions, e.g.
Ca2+, Mg2+ and Zn2+. The occurrence of the HEHEH se-
quence in human proteins could mean that the HE3 tag is a
potentially safer alternative to the His6 tag.
Conclusion
A clinically valuable radioligand for HER2molecular imaging in
breast cancer and gastric cancer would require minimal normal
liver and stomach uptake, as well as the ability to bind to HER2
in the presence of concomitant anti-HER2 therapy. We have
demonstrated that 111In-(HE)3-G3 DARPin has specificity for
HER2, binds in the presence of trastuzumab, and achieves high
tumour-to-blood ratios and reasonable tumour to non-renal tissue
ratios, including tumour-to-liver and tumour-to-stomach ratios.
Based on the presented preclinical data, 111In-(HE)3-G3 could
realize the clinical potential of HER2 imaging and may be
suitable for assessment in a first-in-human study.
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